Corporate Overview

A Road Less Followed

Our story is unique in the world of life sciences investing. We are located at the HudsonAlpha Institute of Biotechnology in Huntsville, Alabama. Not Boston or San Francisco. And unlike the majority of biotech companies, our founding and funding did not follow the traditional, institutional venture capital route.

From our founding in 2007 up until our going public merger transaction in March 2024, we had been largely funded by our founders and investors in the Huntsville life sciences and technology community. These investors followed the team to Serina after the successful exit (via acquisition by Nektar Therapeutics) of the founding team’s prior company, Shearwater Polymers.

At Shearwater, Serina co-founders Dr. Milton Harris and Dr. Michael Bentley developed the first-generation of “PEGylated” drugs. PEG (polyethylene glycol) technology became the standard for delivery of protein drugs and has enabled 30 FDA approved products that have since generated over $140B in cumulative sales. Serina was founded to engineer a next generation polymer therapeutic (our POZ PlatformTM) to address the limitations of PEG and other biocompatible polymer technologies -- enabling new treatment paradigms for patients suffering from some of the world’s most challenging diseases.

Learn More

Latest News

Latest Quarterly Reports

View All Financial Reports